Tips for Successful MAA Submissions in Europe
Bring your questions and join us for an interactive webinar discussing how to navigate the complexities of EU marketing authorization: proven strategies, reduced delays, and approval success.
Date: November 11, 2025
Time: 4:00-5:00 PM CEST/10:00-11:00 AM US EST
Join our experts for part one of our EU regulatory strategy webinar series for an interactive discussion focused on mastering the Marketing Authorization Application (MAA) process.
Securing marketing authorization in Europe requires a deep understanding of regulatory pathways, dossier structure, and evolving EMA expectations. In this interactive webinar, our regulatory experts will walk you through proven, regulator-ready strategies to strengthen your MAA submission—reducing clock-stops, validation defects, and approval delays.
This session will provide actionable insights for navigating every stage of the submission process, from intelligent procedure selection and early scientific advice to airtight Module 3 documentation, benefit–risk narratives, and final labeling coordination. Plus, submit your questions now for our experts to answer during the live session! Our goal is to make this as interactive as possible, so we will also take live questions during the webinar to ensure you are able to get the answers you need.
Attendees will learn how to:
- Choose the optimal route (CP, MRP, or national) and plan for PRIME, Orphan, PIP, and HTA convergence.
- Build a “no-surprises” dossier through strong eCTD hygiene and Module 1 country-specific readiness.
- Strengthen CMC quality and comparability narratives to avoid Day 120 questions.
- Craft persuasive clinical efficacy/safety stories that withstand CHMP scrutiny.
- Minimize delays with targeted RFI planning, labeling alignment, and mock Q&A preparation.
Unable to join? Register and you will receive the recording after the live session.
Make sure you register for part two of the series on EU regulatory strategy, where we will explore how the EU HTA regulations are impacting JCA submissions, and ultimately market access and Marketing Authorization Holders (MAH).
Register for Part Two: The Impact of EU HTA Regulations on JCA Submissions
Join us on November 18, 2025 to continue the conversation around EU Regulatory Strategy as we explore how the EU HTA regulations are impacting JCA submissions, and ultimately market access and Marketing Authorization Holders (MAH).
Meet the Speakers
-
Frank de Vries
Vice President, Strategy, Regulatory Sciences – Development
View Bio
-
Paula van Hennik
Vice President, Clinical, Regulatory Sciences - Development
View Bio
Frank de Vries
Frank has over 30 years of experience in industry in a broad Regulatory Scientific field across all product types and multiple therapeutic areas including (pediatric) rare diseases and leads a team of subject matter experts in Regulatory Sciences to advise, support or lead overall regulatory strategy development and execution.
Frank’s broad and varied experience within the drug development industry includes significant interaction with the European Medicines Agency (EMA) and majority of national regulatory agencies across Europe, Middle East, CIS Region, Africa and to a certain extent LATAM, APAC, Canada, Australia, US. Regulatory interactions include but are not limited to scientific advice/protocol assistance, orphan applications and maintenance, pediatric investigation plans, early interactions, pre-submission meetings with EMA and/or Rapp/Co-Rapp and full marketing authorisation application pre-submission and full procedural support.
Frank has led various due diligence activities for product or portfolio acquisition and supported various Mergers & Acquisitions and served as international expert witness in arbitration court cases. Aside from Regulatory Scientific experience, Frank also held positions in Business Development, In/out-licensing, Commercial, Marketing & Sales, Quality and Pharmacovigilance.
Paula van Hennik
After finalising her PhD in Hematology in 2001 and spending almost 11 years conducting fundamental research on hematopoietic cell migration, Paula joined the Dutch Medicines Evaluation Board early 2012. Initially as clinical assessor, later as senior clinical assessor, with focus on products for oncology, hemato-oncology and hematology. From August 2016 up to February 2023 she was alternate CHMP (Committee for Medicinal Products for Human Use) member representing the Netherlands in this committee. In this committee, deciding on amongst others the benefit/risk of (extensions of) European marketing authorization applications, the oncology, haemato-oncology, part of the benign hematology, female reproductive and osteoporosis products were at the center of her portfolio. These included biologicals, small molecules and advanced (gene and cell) therapy products.
In early 2023 she has started to work at ProPharma, initially as Group Head Clinical and later as Vice President, Clinical, providing procedural support and expert advice to clients with human medical products in various stages of development with the focus on the EU regulatory system.